Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 15/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CASP6 | P55212 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28984925 | 0.82 | AADAT (0.43) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| SCHEMBL28984927 | 0.82 | AADAT (0.43) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| SCHEMBL6362578 | 0.77 | CYP3A4 (0.39) | ROCK2 | |
| Hydrochloric Acid SCHEMBL6362517 | 0.75 | CYP3A4 (0.38) | ROCK2 | |
| SCHEMBL4329501 | 0.74 | FPR2 (0.45) | MEN1KMT2AROCK2 | |
| SCHEMBL14275589 | 0.74 | FPR2 (0.45) | MEN1KMT2AROCK2 | |
| SCHEMBL14635821 | 0.74 | FPR2 (0.45) | MEN1KMT2AROCK2 | |
| SCHEMBL18208519 | 0.74 | P2RX7 (0.44) | P2RX7 | |
| SCHEMBL18208520 | 0.74 | P2RX7 (0.44) | P2RX7 | |
| SCHEMBL8554615 | 0.73 | SLC6A2 (0.47) | MEN1GAAKMT2AROCK2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054457-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | ELZEIN ELFATIH | 2009-02-26 | — | — | US | disclosed |
| US-7452889-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-20080032993-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | ELZEIN ELFATIH | 2008-02-07 | — | — | US | disclosed |
| US-7262198-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2007-08-28 | — | — | US | disclosed |
| EP-1723129-A1 | 1-AKAN-2-OL SUBSTITUTED PIPERAZINE AND PIPERIDINE COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2006-11-22 | — | — | EP | disclosed |
| US-20060229317-A1 | Substituted heterocyclic compounds | ELZEIN ELFATIH | 2006-10-12 | — | — | US | disclosed |
| US-7115610-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20050197346-A1 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. | 2005-09-08 | — | — | US | disclosed |
| WO-2005061470-A1 | 1-AKAN-2-OL SUBSTITUTED PIPERAZINE AND PIPERIDINE COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229317-A1 | Substituted heterocyclic compounds | KCNH1, SDHA, COQ8A | P2RX7 1142/4885MEN1 2276/4885GAA 955/4885 |
| US-20080032993-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | KCNH1, SDHA, COQ8A | P2RX7 1142/4885MEN1 2276/4885GAA 955/4885 |
| US-20090054457-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | KCNH1, SDHA, COQ8A | P2RX7 1142/4885MEN1 2276/4885GAA 955/4885 |
| US-20050197346-A1 | Substituted heterocyclic compounds | KCNH1, SDHA, COQ8A | P2RX7 1142/4885MEN1 2276/4885GAA 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.